This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.
Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down
by Zacks Equity Research
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
by Zacks Equity Research
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
by Zacks Equity Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.
If You Invested $1000 in Molina 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Investors Undervaluing Humana (HUM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Molina Healthcare (MOH) Q2 Earnings Beat, Hikes '22 EPS View
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results gain from membership growth within its Medicaid and Medicare lines of business. A hiked adjusted EPS guidance for 2022 is noteworthy.
Molina (MOH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 4.84% and 6.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Molina, Greif, Arrow, Sonoco and Occidental
by Zacks Equity Research
Molina, Greif, Arrow, Sonoco and Occidental have been highlighted in this Screen of The Week article.
Centene (CNC) Q2 Earnings Beat Estimates, Boosts 2022 View
by Zacks Equity Research
Centene (CNC) currently has $3.4 billion remaining in its share buyback program.
Philips' (PHG) Q2 Earnings Down on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q2 top and bottom-line results reflect the negative impact of supply chain constraints and COVID lockdowns in China.
5 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like MOH, GEF, ARW, SON and OXY that are seeing price strength have a high chance of carrying the momentum forward.
What to Expect From Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Much a $1000 Investment in Molina Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M
by Zacks Equity Research
Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.
Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJH
Centene (CNC) Wins Contract to Serve Delaware's Medicaid Members
by Zacks Equity Research
Centene's (CNC) Delaware subsidiary receives a contract from the State of Delaware's DHSS to efficiently serve the diversified health needs of the state's Medicaid members.
Ensign Group (ENSG) on a Buyout Binge to Boost US Footprint
by Zacks Equity Research
Ensign Group (ENSG) executes a slew of buyouts to offer better healthcare services to the U.S. residents and further penetrate its operational markets.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Factors that Make Molina Healthcare (MOH) an Attractive Bet Now
by Zacks Equity Research
Molina Healthcare (MOH) continues to ride on sustained top-line growth, well-performing Medicare and Medicaid businesses, and a strong cash position.
Is Molina Healthcare (MOH) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna (CI) Divests Units to Chubb for Net $5.1 Billion
by Zacks Equity Research
Cigna (CI) closes the deal to divest its life, accident and supplemental benefits businesses to Chubb. CI primarily intends to pursue share repurchases with proceeds received from the transaction.
3 Reasons Why Molina (MOH) Is a Great Growth Stock
by Zacks Equity Research
Molina (MOH) is well positioned to outperform the market, as it exhibits above-average growth in financials.